2025 · 1st Quarter (Jan 1 - Mar 31)

HARMONY BIOSCIENCES

Filed by HARMONY BIOSCIENCES.

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 18, 2025
Income: Not reported
Expenses: $150,000.00
Registrant: HARMONY BIOSCIENCES
Client: HARMONY BIOSCIENCES
Filing UUID: 5af98c96-7518-4222-bf7f-7d46696c0b2d
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)

Literal federal measure citations: H.R. 5547, H.R. 1492, H.R. 6094, H.R. 6664, H.R. 7384, H.R. 7383, H.R.7024, H.R.3433, S.2897

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.